English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  Coenzyme Q 10  (CoQ 10 ) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ 10  in chronic hemodialysis patients, a population subject to increased oxidative stress.    Methods  We performed a dose escalation study to test the hypothesis that CoQ 10  therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F 2 -isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ 10  concentrations were measured to determine dose, concentration and response relationships.    Results  Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ 10  levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study ( P  = 0.003 vs. baseline and  P  < 0.001 for the effect of dose escalation on isofurans). Plasma F 2 -isoprostane concentrations did not change during the study.    Conclusions  CoQ 10  supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ 10  supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ 10  supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis.    Trial Registration  This clinical trial was registered on clinicaltrials.gov [ NCT00908297 ] on May 21, 2009.

Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress